Unicycive Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	37.37	29.2	26.14	9.7	0.46	16.58
Short-Term Investments	17.22	12.07	-	-	-	-
Cash & Short-Term Investments	54.59	41.27	26.14	9.7	0.46	16.58
Cash Growth	176.12%	57.87%	169.48%	2032.09%	-97.26%	-
Other Current Assets	8.96	7.69	4.81	3.7	2.19	1.83
Total Current Assets	63.55	48.96	30.95	13.4	2.64	18.41
Net Property, Plant & Equipment	0.86	0.17	0.72	0.79	0.17	0.33
Total Assets	64.41	49.14	31.67	14.19	2.82	18.74
Accounts Payable	1.14	0.38	1.06	0.84	0.89	0.74
Accrued Expenses	3.05	1.52	3.56	3.23	2.24	1.21
Current Portion of Leases	0.6	0.12	0.56	0.33	0.16	0.15
Other Current Liabilities	21.7	16.92	18.94	13.13	-	-
Total Current Liabilities	26.49	18.94	24.12	17.53	3.28	2.11
Long-Term Leases	0.22	-	0.12	0.47	-	0.16
Total Long-Term Liabilities	0.22	-	0.12	0.47	-	0.16
Total Liabilities	26.7	18.94	24.24	18	3.28	2.26
Common Stock	0.03	0.02	0.01	0.04	0.02	0.02
Additional Paid-in Capital	178.32	158	108.69	60.7	33.52	32.41
Accumulated Other Comprehensive Income	0.01	-0	-	-	-	-
Retained Earnings	-140.65	-127.83	-101.27	-64.54	-34	-15.94
Shareholders' Equity	37.7	30.2	7.43	-3.81	-0.47	16.48
Total Liabilities & Equity	64.41	49.14	31.67	14.19	2.82	18.74
Total Debt	0.82	0.12	0.68	0.79	0.16	0.31
Net Cash (Debt)	53.77	41.15	25.46	8.91	0.3	16.27
Net Cash Growth	30.66%	61.63%	185.82%	2869.33%	-98.16%	-
Net Cash Per Share	0.01	2.59	3.80	3.63	0.20	13.94
Book Value	37.7	30.2	7.43	-3.81	-0.47	16.48
Book Value Per Share	0.01	1.90	1.11	-1.55	-0.31	14.12
Tangible Book Value	37.7	30.2	7.43	-3.81	-0.47	16.48
Tangible Book Value Per Share	0.01	1.90	1.11	-1.55	-0.31	14.12

SEC Filings: 10-K · 10-Q